NEWS
ENTREVESTOR: IMV Inc. entering a crucial phase in late 2019
Read original article here IMV Inc., the Dartmouth company developing a delivery platform for immunotherapy drugs, is entering a critical phase of its 16-year history as it will soon learn the results of key Phase 2 clinical trials. The company is conducting a range...
Mallinckrodt Agrees to Sell BioVectra Inc. to H.I.G. Capital for $250 Million
Read original news release here -- Transaction continues to advance Mallinckrodt’s strategic focus on branded biopharmaceuticals by monetizing a non-core business -- -- H.I.G. Capital to support BioVectra leadership and its attractive growth plan --...
IMV Announces Research Collaboration with The Wistar Institute to Develop New Targeted Immunotherapy Against the Common BRAF Cancer Mutation
Read original article here September 4, 2019 at 7:05 AM EDT DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--Sep. 4, 2019-- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage immuno-oncology company, today announced a collaboration with The Wistar Institute and Meenhard...
ACOA NEWS RELEASE: Panag Pharma providing effective, non-addictive plant-based pain management
Halifax biotech company developing safe, cutting-edge products to ease chronic pain, inflammation July 11, 2019 – Halifax, NS – Atlantic Canada Opportunities Agency Innovative new treatments for pain management improve the daily lives of Canadians. Panag Pharma Inc....
Entrevestor: Motryx Wins $100K Women’s Fund Grant
Read full ENTREVESTOR article here Halifax-based Motryx, which produces sensors that monitor the storage conditions of blood samples during transport, has been awarded a $97,500 grant from the federally funded Women Entrepreneurship Strategy. CEO Franziska Broell, who...
EVENTS
SOCIAL
Don’t miss our panel session on The Future of Personalized Health & Human Performance featuring Travis McDonough from @Kinduct discussing his work with @NSHAResearch on improving orthopaedic diagnostics and more https://t.co/AYF7adKEfh
It takes many years for pharmaceutical companies to bring their drugs to market and we want to congratulate our members @imv_inc on their Phase 2 clinical trial. Their drug may prolong the lives of people suffering with hard-to-treat forms of cancer. #LifeSciences https://t.co/BCFtQJTVud
Dartmouth-based IMV Inc., developing a delivery platform for #immunotherapy drugs, is entering a critical phase of its 16-year history as it will soon learn the results of key Phase 2 clinical trials. https://t.co/dMdaP4dgZB https://t.co/u9R01lxOmU
ABOUT BIONOVA
Our mandate is to:
- LEAD the development of Health and Life Science in Nova Scotia
- ACCELERATE companies and the business ecosystem
- ADVOCATE for the sector and growth of Nova Scotia’s BioEconomy
OUR SECTOR STRENGTHS
Medical Technologies- Digital Health
- Pharmaceuticals & Vaccines
- Natural Health Products
- BioProducts
Medical Technologies
Digital Health
Pharmaceuticals & Vaccines
Natural Health Products
BioProductsPlease visit our Sector Strengths page to learn more.
OUR ACCELERATION INITIATIVES
BioNova aims to accelerate the innovation and productivity of businesses in Nova Scotia’s bioeconomy through our Projects, Programs, Services & Events with the support of our stakeholders and funding partners.